Clinical Development news from FierceBiotech
News
ALS sees strong data in Phase III antibiotic trial
Advanced Life Sciences is touting data from a recent trial of its antibiotic cethromycin. The therapy produced positive data that it can fight pneumonuia effectively and safely and demonstrated an Read more...
Sanofi buys into Acambis' West Nile vaccine program
Sanofi Pasteur is buying into Acambis' program for a novel West Nile vaccine. Read more...
ALSO NOTED: Novartis plots $700M biotech plant; Genzyme wins marketing approval; Glenmark, Forest to pursue Phase II; and much
> Novartis will plow $700 million into a new cell-culturing facility in Singapore. The plant will boost the drug maker's capacity for biotech drugs, delivering products for commercial distribution Read more...
Targacept pushes depression therapy into the clinic
Targacept is advancing TC-5214 into clinical development as an augmentation therapy for patients who experience an inadequate response to antidepressants. The company expects to initiate a Phase I Read more...
Australian biotech spinoff to develop drugs
The Australian diagnostics company HealthLinx is spinning off two therapies in clinical development into a new company--Proaegis Biosciences--which will hit the road in search of $4 million in Read more...
SPOTLIGHT: Karo Bio reorganizes
Sweden's Karo Bio has trimmed its staff by 14 workers, mostly in administration and R&D, as part of a shakeup aimed at cutting costs as it pushes its pipeline Read more...
Cancer therapy gets accelerated review at Exelixis
Exelixis and GlaxoSmithKline say they're hitting the gas on their program to develop XL880 as a "leading" MET inhibitor for cancer. Exelixis will review the therapy before Read more...
Neuromed banks $53.3M in venture funds
Neuromed Pharmaceuticals has garnered a whopping $53.3 million in Series E funds, bringing its total take in venture capital to $126 million. Much of that money is earmarked for clinical trials, Read more...
Abraxis forges cancer licensing deal with Scripps
Abraxis BioScience and The Scripps Research Institute have inked an exclusive licensing agreement for the worldwide development and commercialization of a novel epothilone therapeutic for the Read more...
Pevion gains $30.2M in first round
Germany's Pevion Biotech has landed a $30.2 million Series A private financing round. The round was led by the new investor BZ Bank Aktiengesellschaft. BB Biotech Ventures II, CC Private Equity Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends